ArticleJournal of surgical oncology2019
Systemic chemotherapy and survival in patients with metastatic low-grade appendiceal mucinous adenocarcinoma.
Article in Journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.JAMA network open · 2023Trial
- Next-Generation Sequencing Identifies Key Targetable Mutations in the Treatment of Appendiceal Neoplasms.Annals of surgical oncology · 2026Article
- Consensus Guideline for the Management of Patients with Appendiceal Tumors, Part 1: Appendiceal Tumors Without Peritoneal Involvement.Annals of surgical oncology · 2026Article
- Article
- Negative Impact of Systemic Therapy on Survival in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Low-Grade Metastatic Appendiceal Adenocarcinoma.Annals of surgical oncology · 2025Article
- New insights in the management of pseudomyxoma peritonei.Journal of surgical oncology · 2024Review
- Outcomes of parenteral nutrition in patients with advanced cancer and malignant bowel obstruction.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Role of colectomy in the management of appendiceal tumors: a retrospective cohort study.BMC gastroenterology · 2023Article
- Outcomes of parenteral nutrition in patients with advanced cancer and malignant bowel obstruction.Research square · 2023Article
- Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma.ESMO open · 2023Article
- The Vermiform Appendix and Its Pathologies.Cancers · 2023Review
- Review
- Durable Response after Repeat Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Extensive Mucinous Adenocarcinoma of the Appendix.Diseases (Basel, Switzerland) · 2023Article
- Advances in the management of peritoneal malignancies.Nature reviews. Clinical oncology · 2022Review
- Article
- Accidental discovery of appendiceal carcinoma during gynecological surgery: A case report.World journal of clinical cases · 2022Article
- The Role of Adjuvant Chemotherapy Following Right Hemicolectomy for Non-metastatic Mucinous and Nonmucinous Appendiceal Adenocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Article
- The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions.Therapeutic advances in medical oncology · 2022Review
- Organoids From Mucinous Appendiceal Adenocarcinomas as High-Fidelity Models for Individual Therapy.Frontiers in medicine · 2022Article
- Chemotherapy in the treatment of different histological types of appendiceal cancers: a SEER based study.BMC cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundAppendiceal cancer is a rare malignancy that exhibits a wide range of histology and treatment response. Given the rarity and heterogeneous nature of the disease, it has been difficult to define optimal treatment strategies. Our goal is to examine the association between use of systemic chemotherapy and survival in patients with metastatic low-grade mucinous appendiceal adenocarcinoma.
methodsThe National Cancer Database (2004-2015) was queried, and patients with mucinous, grade 1, stage IV appendiceal adenocarcinoma were identified. The Kaplan-Meier method was used to calculate survival, and a Cox regression model was used to identify predictors of survival.
resultsSix hundred and thirty-nine patients were identified. Five-year overall survival (OS) for patients undergoing no chemotherapy vs chemotherapy was 52.9% and 61.3%, respectively. After adjusting with Cox proportional hazards model, chemotherapy was not associated with OS (HR:1.1, 95% CI:0.82-1.40, P = 0.61). Patients who underwent surgical resection (HR:0.40, 95% CI:0.28-0.57, P < .001) or were female (HR:0.61, 95% CI:0.5-0.8, P < .001) had improved survival in adjusted analysis.
conclusionsThere is no association between undergoing chemotherapy and OS in this cohort of patients with stage IV low-grade mucinous appendiceal adenocarcinoma. Development of national treatment guidelines is urgently needed for more consistency in the management of patients with appendiceal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.